Seladelpar lysine dihydrate

塞拉德帕赖氨酸二水合物

Report date: 2026/05/05 20:00:16
NME

Base Information

Drug NameSeladelpar lysine dihydrate
Drug Alias Name塞拉德帕SeladelparumSeladelpar司拉德帕LIVDELZI +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor delta agonists
TargetsPeroxisome proliferator-activated receptor delta
Therapy Area/IndicationsFibrosisLiver CirrhosisHepatic Insufficiency +[6] 
Global Approved IndicationsCholangitis, Sclerosing
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/08/14
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesCymabay Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLonza Tampa LLCGilead Sciences IncGilead Sciences Ireland Uc +[6] 
Inactive CompaniesCymabay Therapeutics Inc
Active IndicationsFibrosisLiver CirrhosisHepatic Insufficiency +[5] 
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG